KRAS and cancer: Despite the limited efficacy of phase II trials in NSCLC patients [55], PLK1 is considered a synthetic lethal target in KRAS-mutant cancers, which are proved to be sensitive to mitotic perturbations and hypersensitive to the PLK1 suppression [37].